Screener
Immunovant, Inc. IMVT Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Accounts receivable | 1,133 | 2,084 |
| Prepaid expenses and other current assets | 42,763 | 51,180 |
| Income tax receivable | 2,813 | 427 |
| Total current assets | 948,819 | 767,662 |
| Operating lease right-of-use assets | 72 | 98 |
| Property and equipment, net | 443 | 844 |
| Other assets | 7,680 | 7,618 |
| Total assets | $957,014 | $776,222 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s total current assets?
- Immunovant, Inc. (IMVT) reported total current assets of $948.82M in Q1 2026.
- How has Immunovant, Inc.'s total current assets changed year-over-year?
- Immunovant, Inc.'s total current assets increased by 23.6% year-over-year, from $767.66M to $948.82M.
- What is the long-term trend for Immunovant, Inc.'s total current assets?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s total current assets has grown at a 18.3% compound annual growth rate (CAGR), from $409.01M to $948.82M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Immunovant, Inc.'s total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude